Traiter les neuropathies héréditaires : un rêve qui devient réalité ? [Treating hereditary neuropathies : a dream come true?]
Fiche du document
27 avril 2022
- doi: 10.53738/REVMED.2022.18.779.813
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.779.813
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35481507
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_AB887B5155386
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
TherapyCiter ce document
A. Echaniz-Laguna et al., « Traiter les neuropathies héréditaires : un rêve qui devient réalité ? [Treating hereditary neuropathies : a dream come true?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.779.813
Métriques
Partage / Export
Résumé
Hereditary neuropathies have been the subject of recent major therapeutic advances. Treatments based on antisense oligonucleotides (ASO) and small interfering RNA (siRNA) have been developed and are now commercially available to treat hereditary transthyretin amyloidosis (hTTR) and porphyria. More recently, a CRISPR-Cas9 genomic editing treatment targeting the TTR gene has been developed and is being tested in patients with hTTR. Based on their success in hTTR and porphyria, innovative treatments targeting mRNA and DNA are being evaluated in other hereditary neuropathies, including Charcot-Marie-Tooth disease (CMT).